RESCINDED
Notice Number: NOT-HL-20-757
Key Dates
Release Date: March 17, 2020
First Available Due Date: March 17, 2020
Expiration Date: New Date : May 15, 2020 as per issuance of NOT-HL-20-789
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.
Background
As of March 16, 2020, more than 169,000 cases of COVID-19 and 6,500 deaths have been reported worldwide, with more than 3700 cases and 60 deaths in the United States. The virus binds to the angiotensin-converting enzyme 2 (ACE2) receptor in humans, which is highly expressed in the kidney, endothelium, lung, and heart.
Patients diagnosed with this illness have reported symptoms such as fever, cough, shortness of breath, fatigue, myalgias, headache, sore throat, abdominal pain, and diarrhea. Patients admitted to the hospital generally have pneumonia and abnormal chest imaging, and complications include acute respiratory failure, acute respiratory distress syndrome (ARDS), and acute myocardial injury. ARDS appears to be a significant predictor of mortality. The severity of illness and course of the infection is heterogenous and appears to be more severe in the elderly and in individuals with underlying comorbidities, including cardiovascular and chronic respiratory diseases. To date, SARS-CoV-2 and COVID-19 disease has not caused significant morbidity in infancy and early childhood, a pattern atypical for most viral respiratory diseases.
Research Objectives
To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2, the NHLBI encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and HLB COVID-19 disease. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations.
Possible research interests include but are not limited to the following:
Supplementary funds may be used for the collection of blood or lung samples from human cohorts of individuals with COVID-19 or evidence of SARS-CoV-2 infection or controls, and/or development of novel model systems to expose animals and cells to SARS-CoV-2.
Application and Submission Information
Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequent reissued equivalent.
Administrative supplement work that is proposed through PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) must be within the general scope of the research or training that is already supported. Eligible activity codes for applications to PA-18-591 are limited to the mechanisms listed in PA-18-591.
Applications that involve a change in scope (e.g., the addition of human subjects or children to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) mustapply through PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional). Eligible activity codes for applications to PA-18-935 are limited to the following mechanisms: P01, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U24, U54, UG3, UH3, UM1.
To be eligible for either an Administrative Supplement or Urgent Competitive Revision, the parent award on which the supplement or revision application is based must:
All instructions in the SF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-18-591 or PA-18-935) must be followed, with the following additions:
Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Program staff listed on this NOSI well in advance of the grant receipt date to better determine appropriateness and interest of the NHLBI.
Inquiries
Please direct all inquiries to:
Lora Reineck, MD, MS
National Heart, Lung, and Blood Institute (NHLBI)
Division of Lung Diseases
Telephone: 301-827-7845
Email: lora.reineck@nih.gov
Simone Glynn, MD, MSc, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Division of Blood Diseases and Resources
Telephone: 301-435-0065
Email: glynnsa@nhlbi.nih.gov
Cheryl McDonald, MD
National Heart, Lung, and Blood Institute (NHLBI)
Division of Cardiovascular Sciences
Telephone: 301-435-0560
Email: McDonalC@nhlbi.nih.gov